Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | DBH | P09172 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112286 | 0.84 | ESR1 (0.67) | ESR1ESR2MAPTMEN1ALDH1A1 | |
| SCHEMBL2114738 | 0.84 | ESR1 (0.77) | ESR1ESR2 | |
| SCHEMBL2113569 | 0.84 | ESR1 (1.00) | ESR1ESR2KDM4EHSD17B10 | |
| SCHEMBL2112590 | 0.84 | ESR1 (0.68) | ESR1ESR2CA12CA1CA2 | |
| Gtx-758 SCHEMBL2112794 | 0.80 | ESR1 (1.00) | ESR1ESR2KDM4EHSD17B10 | |
| Gtx-758 SCHEMBL29420202 | 0.80 | ESR1 (1.00) | ESR1ESR2KDM4EHSD17B10 | |
| SCHEMBL2112708 | 0.79 | ESR1 (1.00) | ESR1ESR2KDM4EMEN1KMT2A | |
| SCHEMBL2111934 | 0.79 | HTT (0.61) | ESR1ESR2POLBMAPTMEN1 | |
| SCHEMBL12318272 | 0.78 | ESR1 (0.86) | ESR1ESR2KDM4EPOLBMAPT | |
| SCHEMBL2114817 | 0.78 | ESR1 (0.68) | ESR1ESR2KDM4ECA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | ESR1 7/4885ESR2 3/4885KDM4E 3063/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885KDM4E 1462/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885KDM4E 1462/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885KDM4E 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.